Articles about 'Alastair Compston'

Members have been recognised for their outstanding contribution to society

Professor Patrick Chinnery, an expert in diseases that affect mitochondria – the ‘batteries’ that power our cells – has been appointed as Professor of Neurology and Head of the Department of Clinical Neurosciences at the University of Cambridge. He will take up his appointment on 1 October.

AstraZeneca, its global biologics research and development arm, MedImmune, and the University of Cambridge today announce four new collaborations, building on their existing partnership. The latest collaborations reinforce AstraZeneca’s commitment to research in Cambridge following the company’s decision to locate one of its three global R&D centres and its global headquarters in the city that has been home to MedImmune’s biologics research laboratories for 25 years.

Approval concludes nearly 40-year epic journey from fundamental research to discovery of an effective treatment for active relapsing multiple sclerosis

Alemtuzumab, a drug previously used to treat a type of leukaemia, shown to help people with early multiple sclerosis who relapsed on previous drugs as well as patients who had not yet been treated.

Phase III clinical trials for new MS drug very positive.

Critical insight provided into the disease mechanisms behind multiple sclerosis.

The path from innovation to impact can be long and complex. Here we describe the 30-year journey behind the development of a drug now being used to treat multiple sclerosis.

Cambridge neurologists have shown that an antibody used to treat leukaemia also limits and repairs the damage in multiple sclerosis.